Weekly Analysts’ Ratings Changes for Baxter International (BAX)

Baxter International (NYSE: BAX) recently received a number of ratings updates from brokerages and research firms:

  • 2/6/2018 – Baxter International had its price target raised by analysts at Citigroup Inc from $66.00 to $70.00. They now have a “neutral” rating on the stock.
  • 2/2/2018 – Baxter International had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $72.00 price target on the stock.
  • 2/2/2018 – Baxter International had its price target raised by analysts at Barclays PLC from $73.00 to $77.00. They now have an “overweight” rating on the stock.
  • 2/2/2018 – Baxter International had its price target raised by analysts at BMO Capital Markets from $74.00 to $77.00. They now have an “outperform” rating on the stock.
  • 1/4/2018 – Baxter International was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company's impressive performance at the hospital products and renal segments hold promise. Baxter launched the oXIRIS set for continuous renal replacement therapy (CRRT) and sepsis management protocols in select markets of Europe, Middle East and Africa recently. Further, the recent launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals, boosts the company’s product portfolio. On the flipside, foreign currency headwinds, intensifying competition and lackluster sales growth have been dampening Baxter’s performance since long. Generic competition for cyclophosphamide is an added headwind. Furthermore, the recent hurricanes are expected to dent the company’s results in the near term. Baxter stock looks a tad expensive at the moment.”
  • 1/3/2018 – Baxter International was upgraded by analysts at Raymond James Financial, Inc. from a “market perform” rating to an “outperform” rating. They now have a $73.00 price target on the stock.
  • 1/3/2018 – Baxter International is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $71.00 price target on the stock.
  • 1/2/2018 – Baxter International was upgraded by analysts at Bank of America Corp from a “neutral” rating to a “buy” rating.
  • 1/2/2018 – Baxter International was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating.
  • 12/26/2017 – Baxter International was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the past year, Baxter has outperformed the broader industry in terms of price performance.The company's impressive performance in the third quarter 2017 at the hospital products and renal segments hold promise. Baxter launched the oXIRIS set for continuous renal replacement therapy (CRRT) and sepsis management protocols in select markets of Europe, Middle East and Africa recently. Further, the recent launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals, boosts the company’s product portfolio. The company acquired Claris Injectables recently. On the flipside, a strong U.S. dollar, intensifying competition and lackluster sales growth are key concerns. Generic competition for cyclophosphamide is a headwind. Added to this, the recent hurricanes are expected to dent the company’s results.”

Baxter International Inc (NYSE:BAX) traded up $0.61 on Monday, hitting $64.92. 1,865,971 shares of the stock traded hands, compared to its average volume of 3,495,135. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. Baxter International Inc has a 1 year low of $48.58 and a 1 year high of $72.58. The stock has a market capitalization of $35,190.00, a PE ratio of 49.94, a price-to-earnings-growth ratio of 1.82 and a beta of 0.78.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a net margin of 6.79% and a return on equity of 15.12%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.77 billion. During the same period in the prior year, the business posted $0.57 earnings per share. The company’s revenue was up 4.9% on a year-over-year basis. equities analysts predict that Baxter International Inc will post 2.78 earnings per share for the current year.

In other Baxter International news, SVP Jeanne K. Mason sold 33,350 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the transaction, the senior vice president now directly owns 124,609 shares in the company, valued at approximately $8,130,737.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Giuseppe Accogli sold 28,641 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Receive News & Ratings for Baxter International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply